脑机接口热潮“带飞”三博脑科，私募大佬李曙军“狂揽”28亿浮盈

Core Insights - The article highlights the significant stock price increase of Sanbo Neurosurgery, driven by developments in the brain-computer interface (BCI) sector, particularly following Elon Musk's announcement regarding Neuralink's plans for mass production of BCI devices by 2026 [1][3][4]. Company Performance - Sanbo Neurosurgery's stock price rose to 93.82 yuan per share, marking a 10.45% increase on January 7, 2026, with a cumulative increase of 59.07% since the beginning of the year [1][3]. - The stock reached a peak of 100 yuan per share during trading, reflecting a 17.72% intraday increase [3]. Major Shareholder Insights - TBP3Doctors (HK) Limited, the largest shareholder of Sanbo Neurosurgery, acquired approximately 30.465 million shares at 4.44 yuan per share in December 2015, totaling an investment of 135 million yuan [1][6]. - TBP has since recouped its initial investment through partial share sales, with a current holding valued at approximately 2.834 billion yuan, resulting in a total profit of about 2.885 billion yuan, yielding a return of over 21 times [1][6][7]. Investment Background - TBP is controlled by Li Shujun, founder of Zhi Xin Capital, which manages over 8 billion USD and has invested in notable companies such as Douban and Haier [2][7]. - Li Shujun has a history of successful investments, preferring to acquire significant equity stakes in early-stage companies and later exiting through public offerings [8][9]. Industry Developments - The BCI sector is gaining traction, with Sanbo Neurosurgery being recognized as a leading player due to its strong capabilities in neurosurgery [3][4]. - Recent advancements include the successful completion of the world's first invasive BCI trial in China, which restored motor function in a paralyzed patient [4]. Strategic Investments - Sanbo Neurosurgery is actively investing in the BCI space, committing 87 million yuan to acquire a 29% stake in a venture capital fund focused on brain science tools and early-stage companies in neurological and psychiatric disorders [5]. - Additional investments include 10 million yuan for an 11.11% stake in another fund targeting medical devices for brain disease diagnosis and treatment [5].